Otrivin Menthol

Quick links to important sections

Otrivin Menthol

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Otrivin Menthol

Quick Facts

Property Description
Active ingredient Xylometazoline hydrochloride, Menthol, Eucalyptol (Cineole)
Form Nasal Solution (Spray/Drops)
Pharmacological class Sympathomimetic Agent (Alpha-Adrenergic Agonist)
Common use Relief of Nasal Congestion
Origin Synthetic and Naturally Derived

What is Otrivin Menthol and its Classification?

Otrivin Menthol is a brand-specific Topical Nasal Decongestant classified pharmacologically as a Sympathomimetic Agent and an Alpha-Adrenergic Agonist. This combination product is formulated as an aqueous solution for intranasal administration, generally available Over-the-Counter (OTC) for adult and adolescent use. The primary component, Xylometazoline hydrochloride, is a synthetic imidazoline derivative, a type of medicine that acts locally to manage the physical obstruction of congestion.

Composition, Form, and General Therapeutic Benefit

Otrivin Menthol belongs to the class of Imidazoline derivatives, utilizing Xylometazoline as its core component, an active ingredient clinically recognized for its reliable decongestant effect. Xylometazoline is widely acknowledged for its role as a nasal decongestant and is recognized on the Model List of Essential Medicines for nasal congestion. The product is differentiated by its combination status, featuring the addition of naturally derived Menthol and Eucalyptol (Cineole).

Xylometazoline relieves symptoms of a blocked nose by decreasing swelling. This therapeutic benefit is achieved as Xylometazoline causes vasoconstriction of the blood vessels in the nasal lining. This physical reduction of swelling clears the airways, while the aromatic additives provide a cooling sensory effect that subjectively reinforces the feeling of clear breathing and improved airflow.

Regulatory References

  1. WHO Essential Medicines List

What side effects are possible with Otrivin Menthol?

Possible Side Effects and Safety Information

The official safety profile for Xylometazoline, the core active ingredient in Otrivin Menthol, is structured by regulatory documents to categorize and communicate potential adverse reactions and usage constraints.

Frequency-Classified Adverse Reactions

Adverse reactions are formally grouped by expected frequency. Common effects documented in regulatory sources include local reactions such as nasal dryness, stinging or burning sensations in the nose and throat, sneezing, headache, and nausea. Uncommon effects include hypersensitivity reactions and epistaxis (nosebleed). Very Rare systemic reactions noted are temporary visual disturbances, irregular heart rate, and systemic allergic reactions like angioedema.

Systemic Safety and Constraints

The sympathomimetic nature of the medicine means that in rare cases, systemic absorption may lead to effects on the circulatory and nervous systems. The label specifies potential for palpitations, increased heart rate (tachycardia), and hypertension (high blood pressure). Due to these systemic possibilities, caution is advised for use in patients with pre-existing conditions such as hypertension, cardiovascular disorders, diabetes mellitus, and hyperthyroidism, as defined in the official prescribing information.

Duration-Related Safety Patterns

The regulatory profile explicitly documents safety concerns related to the duration of exposure. Prolonged or excessive use is recognized as leading to potential rebound congestion (Rhinitis Medicamentosa) and possible atrophy of the nasal mucosa. The medicine is also strictly contraindicated in individuals with narrow-angle glaucoma, rhinitis sicca (severe nasal dryness), and following certain surgeries that expose the dura mater.

Overdose and Emergency Response

Overdose and when to seek help

This information is based exclusively on official government regulatory documents detailing the overdose profile of Xylometazoline, the active ingredient in Otrivin Menthol.


Overdose Scope

Element Official Regulatory Documentation
Documented overdose presentations Systemic manifestations include severe dizziness, headache, sedation, palpitations, nausea, vomiting, pallor, and alterations in pupil size.
Physiological systems affected Central Nervous System (CNS), Cardiovascular System (potential for hypertension followed by hypotension, bradycardia, and tachycardia), and Respiratory System (respiratory depression, apnoea).
Population-specific overdose notes Small children are more sensitive to toxicity than adults, with a documented risk of serious depression of the CNS and apnoea in infants.
Emergency-response statements Urgent medical attention must be sought immediately following accidental ingestion or when any signs of overdose are observed. Contact a physician, hospital emergency department, or a Poison Information Centre.

Overdose Classifications (High-Level)

Element Official Regulatory Documentation
Severity classification Potential for severe or life-threatening outcomes, including coma, convulsions (seizures), and respiratory depression.
Overdose-context constraints Management is primarily symptomatic and supportive, as no specific antidote is known. Treatment requires observation for several hours and continuous monitoring of circulation and respiration.

Resulting Overdose Structure

Official overdose statements:

  • The clinical manifestations of overdose involve CNS effects, cardiovascular dysregulation, and systemic signs like hypothermia.
  • Life-threatening outcomes documented in regulatory sources include coma, convulsions, and apnoea (in infants), necessitating urgent medical attention immediately upon suspected overdose.
  • Small children are officially noted to be more susceptible to toxicity and CNS depression.
  • Management protocols are strictly defined as symptomatic and supportive, requiring several hours of medical observation and continuous monitoring of vital signs.

Connection to the overall overdose profile:

Regulatory documents define the overdose profile of Xylometazoline by documenting the potential for severe systemic toxicity, primarily targeting the cardiovascular and central nervous systems. This documented risk profile mandates the official requirement to seek immediate medical care for excessive use or accidental ingestion and establishes that clinical management must focus on symptomatic support and observation in a monitored setting.

Therapeutic Uses of Otrivin Menthol

What Otrivin Menthol Treats: Main Uses and Benefits

The primary role of this medication is to provide localized support for symptom management, focusing on acute congestion and the discomfort it creates. The core active ingredient, Xylometazoline, is considered relevant for the temporary relief of nasal congestion associated with symptoms of a cold, hay fever, or other respiratory allergies.

The medication is commonly used to help manage symptoms associated with conditions characterized by periods of heightened symptoms such as the common cold, seasonal allergic rhinitis (hay fever), and sinus pressure. It is applied across therapeutic domains where short-term symptomatic assistance is needed.

“This medication is primarily relevant for easing the symptoms of physical obstruction in the nose, supporting the patient during difficult episodes by easing distress.”

Quick Fact: Relief for Nasal Congestion

Property Description
Primary Symptom Relieved Physical Nasal Obstruction and Stuffiness
Typical Conditions Common Cold, Sinusitis, Allergic Rhinitis
Main Patient Benefit Contributes to easing the overall symptom load during periods of heightened symptoms

This use supports the patient by managing the physical obstruction and stuffiness and may assist with maintaining functional stability, particularly by facilitating open nasal breathing during the night to contribute to general well-being. It is relevant in contexts involving symptoms that create noticeable physiological strain.

Eligibility and Restrictions for Use

The eligibility for Otrivin Menthol (0.1% strength) is strictly defined by regulatory documents, which establish mandated age requirements and exclusions based on specific health conditions. The medicine is approved for use by adults and adolescents aged 12 years and over.

Contraindicated Populations (Must Not Use)

Population/Condition Regulatory Status
Children Contraindicated for those under 12 years of age.
Glaucoma Contraindicated in patients with narrow-angle glaucoma.
Nasal Conditions Contraindicated in patients with rhinitis sicca (atrophic rhinitis).
Neurosurgery History Contraindicated after trans-sphenoidal hypophysectomy or surgery exposing the dura mater.
MAOI Use Contraindicated if taking Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of stopping them.

Conditional Use and Special Caution

Use requires caution in patients with pre-existing conditions such as hypertension, cardiovascular disease (including long QT syndrome), diabetes mellitus, hyperthyroidism, or prostatic hypertrophy. In view of potential systemic effects, use is generally not recommended during pregnancy. While breastfeeding, the medicine should be used only under medical advice.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Otrivin Menthol (which contains the active ingredient xylometazoline, a sympathomimetic agent) can interact with certain medicinal products and conditions, primarily due to its potential to increase blood pressure or heart rate.

Contraindicated and Restricted Combinations

The most significant interaction is with Monoamine oxidase (MAO) inhibitors, a class of medicine used to treat depression. This product is not recommended for use if you are currently taking an MAO inhibitor or have taken one within the last 14 days. This restriction is mandatory because the combination may lead to a substantial and potentially dangerous increase in blood pressure (hypertensive crisis).

Use with Caution

Caution is advised when using this product concurrently with tri-cyclic and tetra-cyclic antidepressants, as these agents may also increase the systemic effects of xylometazoline, potentially leading to elevated blood pressure and other cardiovascular effects.

Population-Specific Notes

Patients with Long QT syndrome (a specific heart rhythm disorder) should be aware of a known risk. Due to the action of xylometazoline, these patients may be at an increased risk of developing serious ventricular arrhythmias.

Consult a healthcare professional if you are taking any of the medicines mentioned above, have a history of high blood pressure, or have a pre-existing heart condition before using this nasal spray.

Mechanism of Action

alpha1-Adrenergic Receptor Agonism and Nasal Vasoconstriction

The ingredient Xylometazoline acts directly on alpha1-adrenergic receptors found on the nasal mucosa's blood vessels. This targeted activation initiates a signaling cascade that results in the contraction of vascular smooth muscle (vasoconstriction). This promotes detumescence of the nasal tissues due to reduced local blood flow and decreased tissue volume.


TRPM8 Channel Activation and Sensory Cooling

The Menthol component modulates the somatosensory system by activating the Cold and Menthol Receptor 1 (TRPM8) on peripheral nerve endings. Activation of this ion channel generates a specific nerve signal that the brain interprets as a cooling sensation and a perceived airflow sensation. This sensory modulation contributes to the overall physiological adjustment by the drug.


Dual-Action Peripheral Modulation

Otrivin Menthol exerts a peripheral action that combines the two distinct mechanisms: the physical change in tissue volume via vasoconstriction (Xylometazoline) and the sensory perception change (Menthol). This dual peripheral action modulates both vascular tone and somatosensory signaling simultaneously.

Dosage and Administration Information

How Otrivin Menthol is Used: Official Administration Guidelines


The instructions for using this Xylometazoline 0.1% solution follow a standardized administration protocol for approved populations.

Administration Scope

The administration of the Xylometazoline 0.1% solution is limited exclusively to the intranasal route, involving topical application to the nasal mucosa. The official label specifies that for adults and adolescents 12 years of age and over, the standard regimen involves one measured application (spray) into each nostril. The absolute maximum frequency is strictly restricted to three times daily, with a mandatory minimum interval of 8 to 10 hours between subsequent doses to ensure proper spacing. Use of this concentration is strictly not approved for children under 12 years of age.

Procedural Structure and Use Constraints

Prior to the first administration or after a period of non-use, the metered-dose pump requires priming through several initial actuations to ensure correct dose delivery. Instructions indicate the nasal passages should be cleared gently before the spray is applied. The final application of the day is often suggested for administration shortly before bedtime. The overall duration of use is defined as a short-term course, which must not exceed seven consecutive days. This short-term duration is a key constraint on the treatment length. Furthermore, the product container must be used by only one person to prevent the possible spread of infection.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Otrivin Menthol

Evidence for Use in Nasal Congestion from the Common Cold

Research examining the active ingredient in Otrivin Menthol, Xylometazoline, has primarily involved short-term Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time and aimed to study how the physical symptoms of nasal congestion were measured in adults experiencing congestion associated with the common cold or acute upper respiratory episodes.

Studies monitored various outcomes related to physical discomfort. Researchers examined objective measurements like the resistance of the nasal airway to airflow, as well as outcomes describing the patient’s perceived discomfort, such as the subjective feeling of a blocked nose and the outcomes describing the timing of symptom report. Research reported measurements related to objective and subjective nasal congestion over short periods. However, research exploring short-term symptom changes typically focused on the core ingredient, and data for the specific contribution of the combination product featuring menthol and eucalyptol remain limited.


Evidence for Use in Congestion from Allergic Rhinitis and Sinusitis

Research has explored short-term symptom changes in populations with Seasonal Allergic Rhinitis (Hay Fever) and Acute Rhinosinusitis (Sinusitis). Studies explored outcomes related to physical discomfort, focusing on subjective symptom scores for congestion, nasal discharge, and associated facial pressure or pain. Findings describe patterns observed in the studies related to changes in symptoms during acute episodes, with studies monitoring short-term responses.


Long-Term Studies and Follow-up Duration

Otrivin Menthol was evaluated in research exploring short-term symptom changes. In most formal clinical trials, the follow-up durations were limited to less than 7 consecutive days of administration. Long-term effects are not fully established because evidence derived from settings with varying symptom burdens typically ends after one week of use. There is limited information for long-term outcomes related to continuous use.


Evidence in Special Populations and Groups

The primary body of evidence focused mainly on Adults. Research has explored the use of formulations containing the active ingredient in some populations of older children and adolescents (ge 6 or ge 12 years), but results apply only to the specific populations studied. Evidence is limited concerning dedicated studies in older adults, or in individuals with comorbid conditions.

Key Studies & References World Health Organization (WHO) Model List of Essential Medicines

Frequently Asked Questions (FAQ)

Common questions about Otrivin Menthol (FAQ)


Q: How long does the decongestant effect of Otrivin Menthol typically last?

According to official product information, the decongestant effect of the active ingredient, Xylometazoline, is rapid, usually starting within a few minutes. The effect is typically reported to last for up to 10 to 12 hours. This duration is often characterized as providing extended relief from nasal congestion.


Q: Is it normal to feel a burning or stinging sensation right after using Otrivin Menthol?

Yes, common documented side effects of the nasal spray include temporary local reactions. These may involve a transient burning, stinging, or irritation sensation in the nose and throat upon application. For most users, this sensation is reported to be mild and temporary.


Q: How quickly should I expect to feel my nose unblock after using Otrivin Menthol?

Official studies and product information often report that the action of the active decongestant ingredient, Xylometazoline, is generally rapid. The decongestant effect typically starts to be felt within a few minutes of administration.


Q: Can using Otrivin Menthol lead to a 'rebound' congestion issue?

Yes, regulatory warnings state that prolonged or excessive use of this nasal spray beyond the recommended short duration (e.g., more than 7 consecutive days) can lead to a condition called rhinitis medicamentosa, or 'rebound congestion.' This risk is why regulatory guidance emphasizes adherence to the recommended duration of use.


Q: What does 'rebound congestion' from nasal sprays like Otrivin Menthol actually feel like?

Rebound congestion (rhinitis medicamentosa) is the return and often worsening of nasal blockage after the effects of the medicine wear off, especially when the spray has been used for too long. Users often report feeling persistently congested, which may lead to the repeated use of the spray in an attempt to find relief.


Q: Why do some people say they get addicted to nasal sprays like Otrivin Menthol?

The feeling of 'addiction' is a term commonly used by the public to describe the physical phenomenon of rebound congestion. Because prolonged use causes congestion to return quickly, users may feel dependent on the spray to maintain clear breathing. This effect is related to the physiological rebound congestion rather than a true substance dependence.


Q: Does the menthol in Otrivin help with breathing, or is it just for the cooling sensation?

The primary physical decongestant effect (shrinking blood vessels) is achieved by the active ingredient, Xylometazoline. The menthol component works on sensory nerve endings to provide a distinctive cooling sensation and a perceived feeling of increased airflow, which subjectively reinforces the feeling of clearer breathing.


Q: Can I use Otrivin Menthol for a stuffy nose caused by allergies?

Products containing Xylometazoline are generally indicated for the temporary symptomatic relief of nasal congestion. This includes congestion associated with the common cold as well as conditions like hay fever (allergic rhinitis).


Q: Is Otrivin Menthol non-drowsy?

Yes, the product is generally regarded as having no or negligible influence on the ability to drive or operate machinery. While the official adverse event list includes uncommon nervous system effects like headache or irritability, typical drowsiness is not a characteristic side effect.


Q: Can I use Otrivin Menthol if I have a history of sinus problems?

Products containing Xylometazoline are generally indicated for temporary relief of nasal congestion. They may be used as an aid to help drainage of secretions in cases of sinus congestion (sinusitis). Regulatory information advises caution and adherence to short-term use guidelines when using this product.


Q: Why is it important to only use Otrivin Menthol for a short period of time?

Regulatory guidance emphasizes limiting use to a short course, typically no more than seven consecutive days, as specified in regulatory information. This is because prolonged or excessive use significantly increases the risk of developing rebound congestion (rhinitis medicamentosa) and potential long-term damage to the nasal lining.


Q: Are there any documented cases of Otrivin Menthol affecting taste or smell?

Formal adverse event classifications do not typically list changes to taste or smell as common or uncommon effects. However, the product information does note local effects such as irritation, dryness, and in rare cases, hypersensitivity, which could potentially be associated with temporary changes in these senses.


Q: Can using Otrivin Menthol cause temporary changes in heart rate?

Because the active ingredient is a sympathomimetic agent, it has the potential for systemic effects. In very rare cases, regulatory documents note the possibility of irregular or increased heart rate (tachycardia) and palpitations.


Q: Why is it recommended to clear my nose before using Otrivin Menthol?

Official administration guidelines advise clearing the nasal passages gently prior to use. This step helps ensure the medicine can reach the nasal mucosa effectively, supporting the expected decongestant action.


Q: What are the inactive ingredients in Otrivin Menthol besides the active drug and menthol?

In addition to the active ingredient Xylometazoline and Menthol, the product contains Eucalyptol (Cineole). Other typical inactive ingredients, as listed in the full composition, may include purified water, a preservative like benzalkonium chloride, and other excipients such as various salts and stabilizers.


Q: Does Otrivin Menthol help reduce swelling inside the nasal passages?

Yes, a key therapeutic benefit involves reducing swelling. The active ingredient causes vasoconstriction—the narrowing of blood vessels in the nasal lining—which physically reduces the size of the swollen nasal tissues (detumescence), thereby clearing the airways.


Q: Does the menthol component of Otrivin Menthol have any decongestant properties itself?

The primary decongestant action is strictly provided by the Xylometazoline component. The menthol component’s action is sensory only; it provides a cooling sensation and perceived airflow, but it is not formally classified as a physical decongestant that shrinks blood vessels.


Q: Why do some people recommend avoiding Otrivin Menthol before an important meeting?

This social caution is likely linked to the common initial local side effects reported with the spray. Common adverse effects, such as temporary sneezing, stinging, burning, or increased nasal discharge, can be distracting immediately after the spray is administered.


Q: Are there any specific studies on Otrivin Menthol use in the elderly population?

While the main body of clinical evidence focuses on the adult population, official guidance requires caution for use in elderly patients, especially those with pre-existing conditions such as hypertension, cardiovascular disease, or diabetes mellitus.


Q: Is the proper way to use Otrivin Menthol to spray and inhale deeply?

Patient instructions generally advise that the medicine be administered as a measured spray into each nostril. Patient instructions typically describe breathing in gently through the nose at the time the spray is applied, rather than inhaling deeply.


Q: What research is available about the long-term safety of using xylometazoline, the active ingredient in Otrivin Menthol?

Regulatory documents indicate that formal clinical trials focused primarily on short-term symptom relief. Evidence concerning long-term effects is limited, and continuous use beyond the recommended duration carries the risk of rebound congestion.

How should Otrivin Menthol be stored and disposed of?

Official Storage and Disposal Profile (Xylometazoline Hydrochloride)

Official regulatory documents define strict requirements for the storage, stability, and disposal of this medicine, ensuring product quality and safety.

Domain Requirement Summary
Temperature & Environment Store at or below 25 C in a cool, dry place. Protect from excessive heat and direct sunlight.
Stability Period Discard 28 days after first opening. Do not use past the expiration date printed on the packaging.
Safety & Handling Keep out of the reach and sight of children. Store in the original container. For hygiene and infection control, the nasal spray should only be used by one person.
Disposal Instructions Do not dispose of via wastewater or household waste. Return all unused or expired medicine to a pharmacy for safe disposal according to local guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Otrivin Menthol found in:

A-Z Index: